- Home
- GYRE vs HGTY Comparison
GYRE vs HGTY Comparison
Compare GYRE & HGTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- HGTY
- Stock Information
- Founded
- GYRE 2002
- HGTY 1984
- Country
- GYRE United States
- HGTY United States
- Employees
- GYRE N/A
- HGTY N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- HGTY Specialty Insurers
- Sector
- GYRE Health Care
- HGTY Finance
- Exchange
- GYRE Nasdaq
- HGTY Nasdaq
- Market Cap
- GYRE 897.1M
- HGTY 820.4M
- IPO Year
- GYRE N/A
- HGTY N/A
- Fundamental
- Price
- GYRE $7.42
- HGTY $10.05
- Analyst Decision
- GYRE
- HGTY Hold
- Analyst Count
- GYRE 0
- HGTY 3
- Target Price
- GYRE N/A
- HGTY $10.50
- AVG Volume (30 Days)
- GYRE 253.7K
- HGTY 66.5K
- Earning Date
- GYRE 08-12-2025
- HGTY 08-05-2025
- Dividend Yield
- GYRE N/A
- HGTY N/A
- EPS Growth
- GYRE N/A
- HGTY 124.60
- EPS
- GYRE 0.02
- HGTY 0.20
- Revenue
- GYRE $100,643,000.00
- HGTY $1,247,923,000.00
- Revenue This Year
- GYRE $21.04
- HGTY $15.41
- Revenue Next Year
- GYRE $89.64
- HGTY $15.88
- P/E Ratio
- GYRE $93.77
- HGTY $50.01
- Revenue Growth
- GYRE N/A
- HGTY 18.45
- 52 Week Low
- GYRE $6.11
- HGTY $8.03
- 52 Week High
- GYRE $19.00
- HGTY $12.35
- Technical
- Relative Strength Index (RSI)
- GYRE 39.71
- HGTY 63.71
- Support Level
- GYRE $7.26
- HGTY $9.33
- Resistance Level
- GYRE $8.00
- HGTY $10.23
- Average True Range (ATR)
- GYRE 0.49
- HGTY 0.26
- MACD
- GYRE -0.07
- HGTY 0.03
- Stochastic Oscillator
- GYRE 10.36
- HGTY 82.22
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.